Mr
Nathan
Hinks

Patent Director

Manchester Office

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 787 602 9593
Email. [email protected]

Experience

As a UK and European patent attorney, Nathan works with a broad range of clients, including academic institutions, university spin-outs, SMEs and multinational organisations. He has extensive experience of drafting and prosecuting patent applications in the UK and Europe, as well as coordinating the prosecution of his clients’ patent portfolios across the globe.

Nathan’s clients operate across a broad spectrum of chemical technologies, including membranes, polymers, glasses, ceramics, graphene, composite materials, catalysts, coatings, inks, adhesives, cosmetics, and pharmaceuticals formulations. Nathan also provides advice in relation to filing strategies, patentability and freedom-to-operate, and has a history of successes in representing clients at Oral Proceedings before the Examining Division, Opposition Division and Boards of Appeal of the European Patent Office.

Specialisms

  • Catalysis
  • Electrochemistry
  • Household products
  • Material science
  • Petrochemicals
  • Pharmaceutical technologies
  • Physical chemistry
  • Polymer chemistry
  • Printing technologies

Industries

  • Packaging icon Packaging
  • Pharmaceuticals icon Pharmaceuticals

Services

  • Due diligence
  • Patent oppositions & appeals
  • Patents
  • Portfolio management
  • Strategy

Qualifications

Patent Attorney

Chartered (UK)
European


MCHEM

First class honours (University of St Andrews, Scotland)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Law (University of Manchester)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Litigation Certificate

Recognition

Rising Star 2019 (Managing Intellectual Property)

Rising Star 2020 (Managing Intellectual Property)

Publications

MIP IP Rising Stars 2020/2021

View publication online

Related News

EPO Enlarged Board of Appeal decision G4/19 - a European patent application can be refused by reason of the prohibition on double patenting

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can …

Read article

Managing Intellectual Property IP Stars & Firm Rankings 2021

Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …

Read article

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article

G1/21 hearing at the EPO

Follow this page for the updates from G1/21 hearing at the EPO on 28th May 2021. HGF Partners Dr Chris Moore and Douglas Drysdale will be reporting all the key …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.